Mohammad Alkhalil1, Luca Biasiolli2, Naveed Akbar3, Francesca Galassi2, Joshua T Chai2, Matthew D Robson2, Robin P Choudhury4. 1. Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, UK; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 2. Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, UK. 3. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 4. Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, UK; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. Electronic address: robin.choudhury@cardiov.ox.ac.uk.
Abstract
BACKGROUND & AIMS: A recently-validated, highly-sensitive T2 mapping magnetic resonance (MRI) technique accurately quantifies carotid plaque lipid. The aims of this study were to determine: (i) the extent of carotid plaque lipid in patients with acute coronary syndromes (ACS); (ii) the effects of initiation of high-intensity statin on plaque lipid content and (iii) whether plaque lipid content is related to standard or 'functional' blood lipid measurements. METHODS: Statin naïve subjects presenting with ACS underwent carotid artery MRI at 3 T scanner to quantify plaque lipid. Patients were subsequently commenced on high dose statin as part of clinical care and underwent a second MRI after three months. Plaque composition was measured using objective semi-automated techniques. RESULTS: 23 out of 24 patients had measurable lipid. Three months after statin initiation there was a significant reduction in carotid lipid percentage [from 10.3% (7.2-14.2) to 7.4% (5.4-10.0), p = 0.002] and a significant increase in fibrous percentage [from 83.3% ± 6.6-85.5% ± 4.8, p = 0.039]. None of the studied functional blood biomarkers were related to either baseline carotid plaque lipid content or its propensity to change with statin treatment. CONCLUSIONS: T2-mapping demonstrated depleted carotid plaque lipid following the initiation of high-intensity statin treatment. Standard or 'functional' blood biomarkers were dissociated from plaque lipid content or changes with treatment. These findings further reinforce the importance of disease characterisation over risk factor assessment. Subject to clinical trial findings, quantification of plaque lipid may provide the basis for an approach to identify patients suitable for intensive lipid reduction regimes.
BACKGROUND & AIMS: A recently-validated, highly-sensitive T2 mapping magnetic resonance (MRI) technique accurately quantifies carotid plaque lipid. The aims of this study were to determine: (i) the extent of carotid plaque lipid in patients with acute coronary syndromes (ACS); (ii) the effects of initiation of high-intensity statin on plaque lipid content and (iii) whether plaque lipid content is related to standard or 'functional' blood lipid measurements. METHODS: Statin naïve subjects presenting with ACS underwent carotid artery MRI at 3 T scanner to quantify plaque lipid. Patients were subsequently commenced on high dose statin as part of clinical care and underwent a second MRI after three months. Plaque composition was measured using objective semi-automated techniques. RESULTS: 23 out of 24 patients had measurable lipid. Three months after statin initiation there was a significant reduction in carotid lipid percentage [from 10.3% (7.2-14.2) to 7.4% (5.4-10.0), p = 0.002] and a significant increase in fibrous percentage [from 83.3% ± 6.6-85.5% ± 4.8, p = 0.039]. None of the studied functional blood biomarkers were related to either baseline carotid plaque lipid content or its propensity to change with statin treatment. CONCLUSIONS: T2-mapping demonstrated depleted carotid plaque lipid following the initiation of high-intensity statin treatment. Standard or 'functional' blood biomarkers were dissociated from plaque lipid content or changes with treatment. These findings further reinforce the importance of disease characterisation over risk factor assessment. Subject to clinical trial findings, quantification of plaque lipid may provide the basis for an approach to identify patients suitable for intensive lipid reduction regimes.
Authors: Mohammad Alkhalil; Michał Kuzemczak; Nicholas Whitehead; Charalampos Kavvouras; Vladimír Džavík Journal: J Am Heart Assoc Date: 2021-02-15 Impact factor: 5.501
Authors: Robert Frost; Luca Biasiolli; Linqing Li; Katherine Hurst; Mohammad Alkhalil; Robin P Choudhury; Matthew D Robson; Aaron T Hess; Peter Jezzard Journal: Magn Reson Med Date: 2019-11-07 Impact factor: 4.668
Authors: Colin Scott; Sundus S Lateef; Christin G Hong; Amit K Dey; Grigory A Manyak; Nidhi H Patel; Wunan Zhou; Alexander V Sorokin; Khaled Abdelrahman; Domingo Uceda; Meron Teklu; Colin Wu; Philip M Parel; Veit Sandfort; Marcus Y Chen; Marissa Mallek; Mark Ahlman; David Bluemke; Nehal N Mehta Journal: Clin Cardiol Date: 2022-04-02 Impact factor: 3.287
Authors: Ada Weinstock; Karishma Rahman; Or Yaacov; Hitoo Nishi; Prashanthi Menon; Cyrus A Nikain; Michela L Garabedian; Stephanie Pena; Naveed Akbar; Brian E Sansbury; Sean P Heffron; Jianhua Liu; Gregory Marecki; Dawn Fernandez; Emily J Brown; Kelly V Ruggles; Stephen A Ramsey; Chiara Giannarelli; Matthew Spite; Robin P Choudhury; P'ng Loke; Edward A Fisher Journal: Elife Date: 2021-03-15 Impact factor: 8.140